Cited by 643Prostate Cancer Treatment and ResearchChromatin Remodeling and CancerHormonal and reproductive studies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Open access

Watson, Philip A., Chen, Yinan F., Balbas, Minna D., Wongvipat, John, Socci, Nicholas D., Viale, Agnes, Kim, Kwanghee, Sawyers, Charles L.·2010·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1012443107PMC PMC2947883

Open this paper in CoChat — free account

Abstract

Androgen receptor (AR) splice variants lacking the ligand binding domain (ARVs), originally isolated from prostate cancer cell lines derived from a single patient, are detected in normal and malignant human prostate tissue, with the highest levels observed in late stage, castration-resistant prostate cancer. The most studied variant (called AR-V7 or AR3) activates AR reporter genes in the absence of ligand and therefore, could play a role in castration resistance. To explore the range of potential ARVs, we screened additional human and murine prostate cancer models using conventional and next generation sequencing technologies and detected several structurally diverse AR isoforms. Some, like AR-V7/AR3, display gain of function, whereas others have dominant interfering activity. We also find that ARV expression increases acutely in response to androgen withdrawal, is suppressed by testosterone, and in some models, is coupled to full-length AR (AR-FL) mRNA production. As expected, constitutively active, ligand-independent ARVs such as AR-V7/AR3 are sufficient to confer anchorage-independent (in vitro) and castration-resistant (in vivo) growth. Surprisingly, this growth is blocked by ligand binding domain-targeted antiandrogens, such as MDV3100, or by selective siRNA silencing of AR-FL, indicating that the growth-promoting effects of ARVs are mediated through AR-FL. These data indicate that the increase in ARV expression in castrate-resistant prostate cancer is an acute response to castration rather than clonal expansion of castration or antiandrogen-resistant cells expressing gain of function ARVs, and furthermore, they provide a strategy to overcome ARV function in the clinic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1012443107

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Self-citation
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citation
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor
He, B., Kemppainen, J., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 441
Molecular basis of androgen insensitivity
Brinkmann, A. O. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00466-x · Cited by 345

Show all 27 references

Sorted by citations

Items 301–400 of 643

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling
Liu, C., Armstrong, C. M., Ning, S., Yang, J. C., Lou, W., Lombard, A. P., Zhao, J., Wu, C., Yu, A., Evans, C. P., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01914-2 · Cited by 30
Stilbene Induced Inhibition of Androgen Receptor Dimerization: Implications for AR and ARΔLBD-Signalling in Human Prostate Cancer Cells
Streicher, W., Luedeke, M., Azoitei, A., Zengerling, F., Herweg, A., Genze, F., Schrader, M. G., Schrader, A. J., & Cronauer, M. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098566 · Cited by 28
KLF5 Is Crucial for Androgen-AR Signaling to Transactivate Genes and Promote Cell Proliferation in Prostate Cancer Cells
Li, J., Zhang, B., Liu, M., Fu, X., Ci, X., Jun, A., Fu, C., Dong, G., Wu, R., Zhang, Z., et al. (2020) · Cancers · doi:10.3390/cancers12030748 · Cited by 25
Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer
Stinnesbeck, M., Kristiansen, A., Ellinger, J., Hauser, S., Egevad, L., Tolkach, Y., & Kristiansen, G. (2021) · Apmis · doi:10.1111/apm.13117 · Cited by 26
Recent progress in the development of protein–protein interaction inhibitors targeting androgen receptor–coactivator binding in prostate cancer
Biron, É., & Bédard, F. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.006 · Cited by 27
Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression
Qiao, J., Grabowska, M. M., Forestier-Román, I., Mirosevich, J., Case, T. C., Chung, D. H., Cates, J., Matusik, R. J., Manning, H. C., & Jin, R. (2016) · Oncotarget · doi:10.18632/oncotarget.11326 · Cited by 26
Thyroid and androgen receptor signaling are antagonized by μ‐Crystallin in prostate cancer
Aksoy, O., Pěnčík, J., Hartenbach, M., Moazzami, A. A., Schlederer, M., Balber, T., Varady, A., Philippe, C., Baltzer, P., Mazumder, B., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33332 · Cited by 26
Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer
Dellis, A., & Papatsoris, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1548611 · Cited by 24
AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
Kim, S., Au, C. C., Jamalruddin, M. A. B., Abou-Ghali, N. E., Mukhtar, E., Portella, L., Berger, A., Worroll, D., Vatsa, P., Rickman, D. S., et al. (2022) · eLife · doi:10.7554/elife.73396 · Cited by 25
CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer
Sun, R., Wei, T., Ding, D., Zhang, J., Chen, S., He, H. H., Wang, L., & Huang, H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205509119 · Cited by 26
Androgen receptor aberrations in the era of abiraterone and enzalutamide
Jentzmik, F., Azoitei, A., Zengerling, F., Damjanoski, I., & Cronauer, M. V. (2015) · World Journal of Urology · doi:10.1007/s00345-015-1624-2 · Cited by 26
Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines
Ramamurthy, V. P., Ramalingam, S., Gediya, L. K., Kwegyir‐Afful, A. K., & Njar, V. C. O. (2014) · Oncotarget · doi:10.18632/oncotarget.3084 · Cited by 25
WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer
Leach, D. A., Powell, S. M., & Bevan, C. L. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0319 · Cited by 25
Cancer and the metastatic substrate
Arvelo, F. A., Sojo, F. J., & Cotte, C. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.701 · Cited by 25
Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction
Xu, D., Chen, Q., Liu, Y., & Wen, X. (2017) · Oncotarget · doi:10.18632/oncotarget.22319 · Cited by 25
A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers
Maximov, P. Y., Abderrahman, B., Curpan, R. F., Hawsawi, Y. M., Fan, P., & Jordan, V. C. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0416 · Cited by 25
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target
Yeoh, C. C., Dabab, N., Rigby, E., Chhikara, R., Akaev, I., Gomez, R. S., Fonseca, F. P., Brennan, P. A., & Rahimi, S. (2018) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12741 · Cited by 26
An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression
Miyazawa, Y., Sekine, Y., Shimizu, N., Takezawa, Y., Nakamura, T., Miyao, T., Nakayama, H., Kurihara, S., Syuto, T., Nomura, M., et al. (2019) · The Prostate · doi:10.1002/pros.23865 · Cited by 23
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
Kafka, M., Mayr, F., Temml, V., Möller, G., Adamski, J., Hoefer, J., Schwaiger, S., Heidegger, I. M., Matuszczak, B., Schuster, D., et al. (2020) · Cancers · doi:10.3390/cancers12082092 · Cited by 26
Transcriptional mediators of treatment resistance in lethal prostate cancerPreprint
He, M. X., Cuoco, M. S., Crowdis, J. P., Bosma-Moody, A., Zhang, Z., Bi, K., Kanodia, A., Su, M.-J., Rodman, C., DelloStritto, L. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.19.998450 · Cited by 25
Androgen receptor antagonists: a patent review (2008 – 2011)
Mohler, M. L., Coss, C. C., Duke, C. B., Patil, S. A., Miller, D. D., & Dalton, J. T. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.682571 · Cited by 25
Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Singh, K. B., Ji, X., & Singh, S. V. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0117 · Cited by 25
Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
Khurana, N., Chandra, P. K., Kim, H., Abdel‐Mageed, A. B., Mondal, D., & Sikka, S. C. (2020) · Antioxidants · doi:10.3390/antiox9010068 · Cited by 24
Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC
Ji, Y., Zhang, R., Han, X., & Zhou, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115077 · Cited by 24
Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer
Zhang, H., Qi, L., Cai, Y., & Gao, X. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2320301 · Cited by 24
From AR to c-Met: Androgen deprivation leads to a signaling pathway switch in prostate cancer cells
Liu, T., Mendes, D. E., & Berkman, C. E. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2020 · Cited by 24
Androgen receptor footprint on the way to prostate cancer progression
Hodgson, M. C., Bowden, W. A., & Agoulnik, I. U. (2011) · World Journal of Urology · doi:10.1007/s00345-011-0743-7 · Cited by 24
New Hormonal Therapies for Castration-Resistant Prostate Cancer
Mostaghel, E. A., & Plymate, S. R. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.013 · Cited by 26
Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer
Kato, H., Furuya, Y., Miyazawa, Y., Miyao, T., Syuto, T., NOMURA, M., Sekine, Y., Koike, H., Matsui, H., Shibata, Y., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11205 · Cited by 23
Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives
Hu, J., Wang, G., & Sun, T. (2017) · Tumor Biology · doi:10.1177/1010428317692259 · Cited by 25
Targeting AR Variant–Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities
Magani, F., Peacock, S. O., Rice, M. A., Martinez, M. J., Greene, A. M., Magani, P. S., Lyles, R. D. Z., Weitz, J., & Burnstein, K. L. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0280 · Cited by 25
Current strategies for targeting the activity of androgen receptor variants
Armstrong, C. M., & Gao, A. C. (2018) · Asian journal of urology · doi:10.1016/j.ajur.2018.07.003 · Cited by 26
Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer
Alves, I. T., Hartjes, T. A., McClellan, E., Hiltemann, S., Böttcher, R., Dits, N. F. J., Temanni, M.-R., Janssen, B. J., van Workum, W., van der Spek, P. J., et al. (2014) · Oncogene · doi:10.1038/onc.2013.591 · Cited by 25
Modulating the Activity of Androgen Receptor for Treating Breast Cancer
You, C., Tsoi, H., Man, E. P. S., Leung, M., & Khoo, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315342 · Cited by 23
Enhanced Stability and Improved Oral Absorption of Enzalutamide with Self-Nanoemulsifying Drug Delivery System
Lee, S.-M., Lee, J.-G., Yun, T.-H., Cho, J. H., & Kim, K. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021197 · Cited by 25
Androgen Receptor Modulators: A Marriage of Chemistry and Biology
McEwan, I. J. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.69 · Cited by 23
Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
Anantharaman, A., & Friedlander, T. W. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.11.003 · Cited by 23
CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy
Sun, H., Mediwala, S. N., Szafran, A. T., Mancini, M. A., & Marcelli, M. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0257-2 · Cited by 23
AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells
Streicher, W., Zengerling, F., Laschak, M., Weidemann, W. M., Höpfner, M., Schrader, A. J., Jentzmik, F., Schrader, M. G., & Cronauer, M. V. (2012) · World Journal of Urology · doi:10.1007/s00345-012-0842-0 · Cited by 25
Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure
Urbanucci, A., Marttila, S., Jänne, O. A., & Visakorpi, T. (2011) · The Prostate · doi:10.1002/pros.22473 · Cited by 22
Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients
Mellado, B., Jiménez, N., Marín‐Aguilera, M., & Reig, Ò. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.12.030 · Cited by 22
Coordinated AR and microRNA regulation in prostate cancer
Eringyte, I., Losada, J. N. Z., Powell, S. M., Bevan, C. L., & Fletcher, C. E. (2020) · Asian journal of urology · doi:10.1016/j.ajur.2020.06.003 · Cited by 24
The heat of the battle: inflammation’s role in prostate cancer development and inflammation-targeted therapies
Sharma, U., Sahu, A., Shekhar, H., Sharma, B., Haque, S., Kaur, D., Tuli, H. S., Mishra, A., & Ahmad, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-01829-4 · Cited by 21
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models
Xu, P., Yang, J. C., Ning, S., Chen, B., Nip, C., Wei, Q., Liu, L., Johnson, O. T., Gao, A. C., Gestwicki, J. E., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106692 · Cited by 24
Nuclear receptors and endobiotics glucuronidation: the good, the bad, and the UGT
Bigo, C., Caron, S., Dallaire-Théroux, A., & Barbier, O. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.751992 · Cited by 21
Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer
Niraula, S., Chi, K., & Joshua, A. M. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0096-0 · Cited by 21
Strategies for targeting the androgen receptor axis in prostate cancer
Carver, B. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.07.008 · Cited by 21
Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer
Braadland, P. R., & Urbanucci, A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0579 · Cited by 21
Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy
Ma, T., Bai, S., Qi, Y., Zhan, Y., Ungerleider, N., Zhang, D. Y., Neklesa, T. K., Corey, E., Dehm, S. M., Zhang, K., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.037 · Cited by 21
Androgen Receptor in Human Health: A Potential Therapeutic Target
Siddique, H. R., Nanda, S., Parray, A., & Saleem, M. (2012) · Current Drug Targets · doi:10.2174/138945012804545579 · Cited by 20
The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions.
Tilki, D., & Evans, C. P. (2014) · PubMed · Cited by 20
High mobility group protein AT‐hook 1 (HMGA1) is associated with the development of androgen independence in prostate cancer cells
Takeuchi, I., Takaha, N., Nakamura, T., Hongo, F., Mikami, K., Kamoi, K., Okihara, K., Kawauchi, A., & Miki, T. (2011) · The Prostate · doi:10.1002/pros.22460 · Cited by 19
Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells
Wilson, S., Cavero, L., Tong, D., Liu, Q., Geary, K. R., Talamonti, N., Xu, J., Fu, J., Jiang, J., & Zhang, D. (2017) · Oncotarget · doi:10.18632/oncotarget.18003 · Cited by 19
Molecular mechanisms of enzalutamide resistance in prostate cancer
Blatt, E. B., & Raj, G. V. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.25 · Cited by 19
Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint
Yu, B., Liu, Y., Luo, H., Fu, J., Yang, L., & Shao, C. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100276 · Cited by 18
The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy
Fiandalo, M. V., Wu, W., & Mohler, J. L. (2013) · Current Drug Targets · doi:10.2174/1389450111314040004 · Cited by 19
The Presence of Androgen Receptor Elements Regulates ZEB1 Expression in the Absence of Androgen Receptor
Mooney, S. M., Parsana, P., Hernandez, J. R., Liu, X., Verdone, J. E., Torga, G., Harberg, C. A., & Pienta, K. J. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24948 · Cited by 19
C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer
Azoitei, A., Merseburger, A. S., Godau, B., Hoda, M. R., Schmid, E., & Cronauer, M. V. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.06.008 · Cited by 20
The role of androgens and global and tissue-specific androgen receptor expression on body composition, exercise adaptation, and performance
Barsky, S. T., & Monks, D. A. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00707-6 · Cited by 20
Testosterone boosts for treatment of castration resistant prostate cancer: An experimental implementation of intermittent androgen deprivation
Thelen, P., Heinrich, E., Bremmer, F., Trojan, L., & Strauß, A. (2013) · The Prostate · doi:10.1002/pros.22711 · Cited by 18
Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer
Bedoya, D., & Mitsiades, N. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.196 · Cited by 18
Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells
Ma, Y., Miao, Y., Peng, Z., Sandgren, J., de Ståhl, T. D., Huss, M., Lennartsson, L., Liu, Y., Nistér, M., Nilsson, S. F., et al. (2016) · SpringerPlus · doi:10.1186/s40064-016-3543-0 · Cited by 18
Performance comparison of two androgen receptor splice variant 7 (AR‐V7) detection methods
Bernemann, C., Steinestel, J., Humberg, V., Bögemann, M., Schrader, A. J., & Lennerz, J. K. (2018) · British Journal of Urology · doi:10.1111/bju.14146 · Cited by 17
To Die or to Survive, a Fatal Question for the Destiny of Prostate Cancer Cells after Androgen Deprivation Therapy
Zhang, K., Firus, J., Prieur, B., Jia, W. W.-G., & Rennie, P. S. (2011) · Cancers · doi:10.3390/cancers3021498 · Cited by 18
Effects of Sorafenib on C-Terminally Truncated Androgen Receptor Variants in Human Prostate Cancer Cells
Zengerling, F., Streicher, W., Schrader, A. J., Schrader, M. G., Nitzsche, B., Cronauer, M. V., & Höpfner, M. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911530 · Cited by 17
Potential molecular targeting of splice variants for cancer treatment.
Blair, C. A., & Zi, X. (2011) · PubMed · Cited by 17
Androgen receptor gene polymorphisms and alterations in prostate cancer: Of humanized mice and men
Robins, D. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.003 · Cited by 17
On the Origins of the Androgen Receptor Low Molecular Weight Species
Mudryj, M. M., & Tepper, C. G. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0152-z · Cited by 20
Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer
Chen, Y., & Lan, T. (2020) · Urologia Internationalis · doi:10.1159/000510124 · Cited by 17
RNA biomarkers to facilitate the identification of aggressive prostate cancer
Pellegrini, K. L., Sanda, M. G., & Moreno, C. S. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.003 · Cited by 17
Role of bromodomain and extraterminal (BET) proteins in prostate cancer
Mandl, A., Markowski, M. C., Carducci, M. A., & Antonarakis, E. S. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2186851 · Cited by 16
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
Miller, C. D., Likasitwatanakul, P., Toye, E., Hwang, J. H., & Antonarakis, E. S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2405103 · Cited by 15
Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
Inoue, T., & Ogawa, O. (2011) · Prostate Cancer · doi:10.1155/2011/647987 · Cited by 16
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer
Pal, S. K., & Sartor, O. A. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.10.009 · Cited by 16
Human C-terminally truncated ERα variants resulting from the use of alternative exons in the ligand-binding domain
Hattori, Y., Ishii, H., Munetomo, A., Watanabe, H., Morita, A., Sakuma, Y., & Ozawa, H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.01.026 · Cited by 16
Precision medicine for prostate cancer
Galazi, M., Rodríguez‐Vida, A., Ng, T., MASON, M. D., & Chowdhury, S. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.972948 · Cited by 16
Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer
Hillebrand, A. C., Pizzolato, L. S., Neto, B. S., Branchini, G., & Brum, I. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200613 · Cited by 17
Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview
Blatt, E. B., Kopplin, N. G., Kumar, S., Mu, P., Conzen, S. D., & Raj, G. V. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0272 · Cited by 15
Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
Wüstmann, N., Seifert, K. E., Humberg, V., Vieler, J., Grundmann, N., Steinestel, J., Tiedje, D., Duensing, S. M., Krabbe, L., Bögemann, M., et al. (2023) · Biomarker Research · doi:10.1186/s40364-023-00481-w · Cited by 16
Functional implications and therapeutic targeting of androgen response elements in prostate cancer
Senapati, D., Sharma, V., Rath, S. K., Rai, U., & Panigrahi, N. (2023) · Biochimie · doi:10.1016/j.biochi.2023.07.012 · Cited by 15
Emerging role of miRNA in prostate cancer: A future era of diagnostic and therapeutics
Khan, M. M., Sharma, V., & Serajuddin, M. (2023) · Gene · doi:10.1016/j.gene.2023.147761 · Cited by 16
Therapeutic Approaches to Targeting Androgen Receptor Splice Variants
Daniels, V. A., Luo, J., Paller, C. J., & Kanayama, M. (2024) · Cells · doi:10.3390/cells13010104 · Cited by 16
Androgen receptor: Structure, signaling, function and potential drug discovery biomarker in different breast cancer subtypes
Shukla, N., Shah, K., Rathore, D., Soni, K., Shah, J., Vora, H., & Dave, H. V. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122697 · Cited by 15
Castration-resistant prostate cancer: potential targets and therapies
Saleem, M., Siddique, H. R., Konety, B. R., Nanda, S., & Parray (2012) · Biologics · doi:10.2147/btt.s23954 · Cited by 15
Overcoming castration resistance in prostate cancer
Tsao, C., Small, A., Galsky, M. D., & Oh, W. K. (2012) · Current Opinion in Urology · doi:10.1097/mou.0b013e3283523b8b · Cited by 15
PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
Liu, W., Wang, C., Wang, S., Zeng, K., Wei, S., Sun, N., Sun, G., Wang, M., Zou, R., Liu, W., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.50810 · Cited by 15
Modeling Truncated AR Expression in a Natural Androgen Responsive Environment and Identification of RHOB as a Direct Transcriptional Target
Tsai, H.-C., Boucher, D. L., Martinez, A. D., Tepper, C. G., & Kung, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049887 · Cited by 16
Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model
Nakata, D., Nakayama, K., Masaki, T., Tanaka, A., Kusaka, M., & Watanabe, T. (2016) · The Prostate · doi:10.1002/pros.23238 · Cited by 14
The Genetic Complexity of Prostate Cancer
Compérat, É., Wasinger, G., Oszwald, A., Kain, R., Cancel‐Tassin, G., & Cussenot, O. (2020) · Genes · doi:10.3390/genes11121396 · Cited by 14
A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research
Laccetti, A. L., Morris, M. J., & Kantoff, P. W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s242921 · Cited by 16
Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer
Huang, F., Li, K., Shevach, J. W., & Wang, Q. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.04.004 · Cited by 18
Lessons from in-vivo models of castration-resistant prostate cancer
Lin, D., Gout, P. W., & Wang, Y. Z. (2013) · Current Opinion in Urology · doi:10.1097/mou.0b013e32835e9f07 · Cited by 14
Sequencing of agents for castration-resistant prostate cancer.
Hurwitz, M. E., & Petrylak, D. P. (2013) · PubMed · Cited by 14
Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor
Minges, J. T., Grossman, G., Zhang, P., Kafri, T., & Wilson, E. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.663641 · Cited by 15
Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
Kohli, M., Qin, R., Jiménez, R. E., & Dehm, S. M. (2012) · Advances in Urology · doi:10.1155/2012/781459 · Cited by 14
Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.
Namiki, M., Ueno, S., & Kitagawa, Y. (2012) · PubMed Central · doi:10.3978/j.issn.2223-4683.2012.07.03 · Cited by 15
Modulation of testosterone-dependent male sexual behavior and the associated neuroplasticity
Charlier, T. D., Seredynski, A. L., Niessen, N., & Balthazart, J. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2013.03.003 · Cited by 14
Expression of β-catenin and Mesenchymal Markers in Canine Prostatic Hyperplasia and Carcinoma
Lean, F. Z. X., Kontos, S., & Palmieri, C. (2014) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2013.12.008 · Cited by 14
Beyond Androgen Deprivation
McCarty, M. F., Hejazi, J., & Rastmanesh, R. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414534728 · Cited by 14
Recent Advances in Allosteric Androgen Receptor Inhibitors for the Potential Treatment of castration-resistant Prostate Cancer
Martinez‐Ariza, G., & Hulme, C. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.20 · Cited by 14

Authors: Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Human Oncology and Pathogenesis Program,
Bioinformatics Core,
University of California, Los Angeles (US)
Howard Hughes Medical Institute (US)
Corresponding author: Sawyers, Charles L.
ORCID: Watson, Philip A.
Socci, Nicholas D.
Viale, Agnes
Kim, Kwanghee
Sawyers, Charles L.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2010-09-07
Volume: 107
Issue: 39
Pages: 16759-16765
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1012443107
PMC: PMC2947883
OpenAlex: W2083926838
Cited by: 639
References: 27
Citations by year: 2026: 8 · 2025: 19 · 2024: 22 · 2023: 33 · 2022: 25 · 2021: 26 · 2020: 43 · 2019: 33 · 2018: 36 · 2017: 43 · 2016: 63 · 2015: 48 · 2014: 64 · 2013: 65 · 2012: 53
FWCI: 46.52
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
Prostate Cancer Foundation
University of Washington
National Cancer Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords: androgen receptor splice variants, castration-resistant prostate cancer, AR-V7, ligand-independent receptor activation, full-length androgen receptor, androgen withdrawal, antiandrogen resistance, enzalutamide, anchorage-independent growth, siRNA knockdown, prostate cancer cell lines, androgen receptor isoforms
MeSH terms: Amino Acid Sequence, Androgens, Animals, Castration, Disease Models, Animal, Exons, Humans, Male, Molecular Sequence Data, Prostatic Neoplasms, Receptors, Androgen, RNA, Messenger, Gene Expression Regulation, Neoplastic, Alternative Splicing, Protein Structure, Tertiary, Sequence Analysis, Protein, Cell Line, Tumor, Mice, Androgen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks